Thrivent Financial for Lutherans’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-37,636
Closed -$2.47M 2497
2025
Q2
$2.47M Buy
37,636
+1,701
+5% +$111K 0.01% 1217
2025
Q1
$2.54M Buy
35,935
+2,019
+6% +$140K 0.01% 1129
2024
Q4
$2.23M Buy
33,916
+1,407
+4% +$96.8K ﹤0.01% 1350
2024
Q3
$2.29M Buy
32,509
+6,214
+24% +$433K ﹤0.01% 1349
2024
Q2
$1.74M Buy
26,295
+2,272
+9% +$149K ﹤0.01% 1472
2024
Q1
$1.63M Buy
24,023
+2,672
+13% +$177K ﹤0.01% 1567
2023
Q4
$1.32M Buy
21,351
+5,556
+35% +$327K ﹤0.01% 1666
2023
Q3
$932K Buy
15,795
+3,510
+29% +$215K ﹤0.01% 1788
2023
Q2
$733K Buy
12,285
+936
+8% +$55.6K ﹤0.01% 1997
2023
Q1
$663K Buy
11,349
+1,425
+14% +$85.8K ﹤0.01% 2008
2022
Q4
$616K Buy
9,924
+603
+6% +$36.3K ﹤0.01% 2019
2022
Q3
$527K Buy
9,321
+378
+4% +$23.3K ﹤0.01% 2052
2022
Q2
$571K Sell
8,943
-1,857
-17% -$118K ﹤0.01% 2028
2022
Q1
$699K Buy
+10,800
New +$685K ﹤0.01% 2030

Other funds holding IHE

Thrivent Financial for Lutherans's IHE Position: Q3 2025 in Review

Thrivent Financial for Lutherans sold out of iShares US Pharmaceuticals ETF (IHE) in Q3 2025, closing a stake of 37,636 shares — an estimated $2.47M sold.

Thrivent Financial for Lutherans first reported a position in IHE in Q1 2022 and held it in 14 quarters. The position peaked at $2.54M in Q1 2025. 150 funds tracked by Wall St. Rank hold IHE as of Q3 2025.

  • Thrivent Financial for Lutherans reported no remaining iShares US Pharmaceuticals ETF position as of Q3 2025 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 37,636 iShares US Pharmaceuticals ETF shares in Q3 2025, an estimated $2.47M.
  • Thrivent Financial for Lutherans first reported a position in iShares US Pharmaceuticals ETF in Q1 2022 and held it in 14 quarters.
  • Thrivent Financial for Lutherans's iShares US Pharmaceuticals ETF position peaked at $2.54M in Q1 2025.
  • 150 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2025, filed 4 Nov 2025.